Janssen Belgium
Janssen Belgium is a Johnson & Johnson pharmaceutical subsidiary based in Beerse, Belgium, developing and commercializing oncology and hematology therapies including DARZALEX FASPRO and RYBREVANT for multiple myeloma and head and neck cancer patients globally.
- Company typePrivate
- Founded1953
- HeadquartersBeerse, Belgium
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Janssen Belgium does
Janssen Belgium is a pharmaceutical subsidiary of Johnson & Johnson, headquartered in Beerse, Belgium, founded in 1953, and operating with a workforce of 10,000+ employees. Its therapeutic focus is oncology and hematology, anchored by two flagship assets: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), which in November 2025 became the first and only FDA-approved treatment for high-risk smoldering multiple myeloma, and RYBREVANT (amivantamab), a subcutaneous EGFR/MET-directed bispecific antibody whose Phase 1b/2 data showed a 45% overall response rate in recurrent or metastatic head and neck squamous cell carcinoma. The company invests in proprietary drug-delivery technologies, including subcutaneous co-formulations, and supports these with internal R&D across exploratory biology, computational sciences, machine learning, and clinical innovation.
The business model operates through Johnson & Johnson's pharmaceutical segment, generating revenue by developing, manufacturing, and selling patented biologic therapies globally across the US and EMEA. Pricing is not publicly disclosed and reimbursement flows through national formularies, hospital systems, and private payers. In 2023 Janssen restructured by cutting its infectious disease and vaccine units, ending its prior Arrowhead Pharmaceuticals partnership and concentrating capital on oncology and hematology. Acquisition history includes XO1 (2015) and Corimmun (2012), both undisclosed-value deals that extended its pipeline. Customer reach is broad across patient populations, but revenue concentration sits in a narrow set of high-value oncology franchises, making pipeline success the primary value driver for the entity.
Janssen Belgium firmographics
Firmographics- Name
- Janssen Belgium
- Website
- https://janssen.com
- Company type
- Private
- Founded year
- 1953
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Janssen Belgium is a Johnson & Johnson pharmaceutical subsidiary based in Beerse, Belgium, developing and commercializing oncology and hematology therapies including DARZALEX FASPRO and RYBREVANT for multiple myeloma and head and neck cancer patients globally.
- Ownership category
- akta.pro rank
Janssen Belgium industry classification
Industry- Product category
- Oncology and Hematology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)
Keywords
Where Janssen Belgium is headquartered
LocationHeadquarters
- HQ city
- Beerse
- HQ country
- Belgium
- HQ region
- Europe
Markets served
Janssen Belgium business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Janssen Belgium product offering
Product offeringCore offering
Janssen Belgium develops, manufactures, and commercializes pharmaceutical medicines focused on oncology and hematology therapeutic areas. Its product portfolio includes DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous treatment approved by the U.S. FDA for high-risk smoldering multiple myeloma, and RYBREVANT® (amivantamab), a subcutaneous bispecific antibody being evaluated for head and neck cancer and other EGFR/MET-driven solid tumors. The company operates as the pharmaceutical subsidiary of Johnson & Johnson.
Product overview
Janssen Belgium operates as part of Johnson & Johnson's pharmaceutical division, focused on delivering innovative medicines. The product portfolio includes DARZALEX FASPRO® (the first and only FDA-approved treatment for high-risk smoldering multiple myeloma) and RYBREVANT® (amivantamab), a subcutaneous therapy demonstrating efficacy in head and neck cancer with broad potential across EGFR/MET-driven solid tumors. These treatments represent Janssen's oncology and hematology therapeutic areas.
Differentiator
Problem solved
Functional benefit
Brands
- DARZALEX FASPRO: First and only FDA-approved treatment for high-risk smoldering multiple myeloma
- RYBREVANT (amivantamab)
- RYBREVANT
Products and services
- DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) A subcutaneous monoclonal antibody treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma. It is the first and only approved treatment for this indication, based on Phase 3 study results demonstrating significant reduction in disease progression to active multiple myeloma.
- RYBREVANT® (amivantamab) Subcutaneous Formulation A subcutaneous bispecific antibody formulation of amivantamab being evaluated for treatment of recurrent or metastatic head and neck squamous cell carcinoma. Demonstrates broad potential across solid tumors driven by EGFR and MET pathways, with subcutaneous administration enabling improved patient convenience and dosing.
Quantifiable outcome
- Phase 3 study demonstrated significant reduction in disease progression for high-risk smoldering multiple myeloma patients
- +1 more outcomes
Companies that use Janssen Belgium
Customer profileSegments2 records
Ideal customer profiles1 record
Janssen Belgium technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Janssen Belgium partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Arrowhead PharmaceuticalsminorJohnson & Johnson previously held a partnership with Arrowhead Pharmaceuticals through its Janssen subsidiary focused on infectious disease and vaccine development. J&J liquidated 247,598 Arrowhead shares, exiting its stake in the company. The partnership ended in 2023 after Janssen cut its infectious disease and vaccine units as part of strategic restructuring.
Scale indicators1 record
Recent moves5 records
Expansion highlights5 records
Janssen Belgium competitors and assessment
Company assessmentMarket position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
Janssen Belgium social profiles
Digital presenceJanssen Belgium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Janssen Belgium leadership team
Management profileNumber of profiles
Profiles24 records
Janssen Belgium funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Janssen Belgium M&A and investment
M&A and investmentM&A2 records
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Janssen Belgium
What does Janssen Belgium do?
Janssen Belgium develops, manufactures, and commercializes pharmaceutical medicines focused on oncology and hematology therapeutic areas. Its product portfolio includes DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous treatment approved by the U.S. FDA for high-risk smoldering multiple myeloma, and RYBREVANT® (amivantamab), a subcutaneous bispecific antibody being evaluated for head and neck cancer and other EGFR/MET-driven solid tumors. The company operates as the pharmaceutical subsidiary of Johnson & Johnson.
Is Janssen Belgium a public or private company?
Janssen Belgium is a private company. It is classified as corporate owned and is currently operating.
When was Janssen Belgium founded?
Janssen Belgium was founded in 1953. It employs 5,001 to 10,000 people.
Where is Janssen Belgium based?
Janssen Belgium is headquartered in Beerse, Belgium, in the Europe region.
Does Janssen Belgium have an API?
No public API is recorded for Janssen Belgium.
What industry is Janssen Belgium in?
Janssen Belgium's product category is Oncology and Hematology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.